• Recordati’s H1 2026 results call drew CEO Rob Koremans, CFO Mike McClellan, EVPs Scott Pescatore, Alberto Martinez, Milan Zdravkovic, IR VP Eugenia Litz.
• H1 revenue EUR 1.4 billion; EBITDA EUR 540 million; free cash flow EUR 299.4 million; net debt below 1.9x EBITDA.
• Rare disease revenue rose 17.1% to EUR 604 million; Isturisa grew 58%; Enjaymo rose 31.1%.
• Isturisa U.S. conversion improved in Q2, with over 20% more conversions than Q1; churn eased as insurance effects moderated.
• 2026 guidance reaffirmed: net revenue EUR 2.73-2.8 billion; EBITDA EUR 995 million-EUR 1.3 billion; adjusted net income EUR 655-685 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Recordati Industria Chimica e Farmaceutica S.p.A. published the original content used to generate this news brief on September 01, 2026, and is solely responsible for the information contained therein.